Haemato AG
HAEK | F
Overview
Corporate Details
- ISIN(s):
- DE000A289VV1
- LEI:
- 529900Q3CGRYVCW7E340
- Country:
- Germany
- Address:
- Lilienthalstraße 3a, 12529 Schönefeld
- Website:
- https://haemato.de/en/start.html
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
HAEMATO has been committed for over 15 years as a pharmaceutical manufacturer and wholesaler to actively contributing to cost reduction in the healthcare sector, so that every patient can benefit from the latest therapies and treatment concepts, even if these are often very expensive. In addition, the Group focuses on the development and distribution of own brands in the Lifestyle & Aesthetics segment. HAEMATO covers chronic diseases and high-priced therapies in particular with its own product portfolio. The focus is on the five therapeutic areas of HIV/AIDS, neurology, oncology, rheumatology and ophthalmology. These therapeutic areas include innovative, patent-protected drugs as well as biosimilars and generics. The product portfolio is rounded off with narcotics, which also include cannabis products.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-04-10 00:00 |
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
|
German | 314.8 KB | |
| 2025-01-15 00:00 |
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
|
German | 30.6 KB | |
| 2024-09-26 00:00 |
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
|
German | 56.0 KB | |
| 2024-02-09 00:00 |
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
|
German | 343.3 KB | |
| 2023-12-12 00:00 |
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
|
German | 61.5 KB | |
| 2023-11-30 14:14 |
Delisting Announcement
HAEMATO AG: Termination of listing in the Open Market
|
English | 8.7 KB | |
| 2023-11-16 08:21 |
Earnings Release
HAEMATO AG publishes figures for the third quarter of 2023: Sales increase o…
|
English | 15.5 KB | |
| 2023-11-15 19:42 |
Regulatory News Service
Termination of the botulinum toxin project
|
English | 8.1 KB | |
| 2023-10-30 00:00 |
Interim Report
Half-yearly financial statements 2023
|
English | 1.8 MB | |
| 2023-10-30 00:00 |
Interim Report
Half-yearly financial statements 2023
|
English | 1.8 MB | |
| 2023-08-31 09:00 |
Earnings Release
HAEMATO AG publishes figures for the first half of 2023
|
English | 9.7 KB | |
| 2023-06-09 00:00 |
Annual Report
Annual financial statements 2022
|
English | 5.9 MB | |
| 2023-06-09 00:00 |
Annual Report
Annual financial statements 2022
|
English | 5.9 MB | |
| 2023-05-31 16:34 |
Earnings Release
HAEMATO AG with a strong start into the year 2023: Revenue increase of over 2…
|
English | 8.6 KB | |
| 2023-05-16 17:40 |
Notice of Dividend Amount
HAEMATO AG: Dividend of EUR 1.20
|
English | 5.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP | |
| ASKA Pharmaceutical Holdings CO., Ltd. | Japan | 4886 | ||
|
Astellas Pharma Inc. | Japan | 4503 | |
|
AstraZeneca PLC | United Kingdom | AZN | |
|
Basilea Pharmaceutica AG | Switzerland | BSLN | |
|
Bayer AG | Germany | BAY | |
|
Biofarm S.A. | Romania | BIO | |
|
Biogened Spolka Akcyjna | Poland | BGD |